Tachycardia (Tachyarrhythmias) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Tachycardia (Tachyarrhythmias) – Drugs In Development, 2024 report and make more profitable business decisions.
Tachycardia also known as tachyarrhythmias is a condition where heartbeats >100 beats per minute, which is faster than normal heartbeat. Tachycardia is commonly observed during running, exercise, shock, or anxious cases but it is a concern when occurring at rest. There are 3 types of tachycardia which are sinus, ventricular and supraventricular. Sinus tachycardia commonly occurs after a strenuous exercise, in supraventricular tachycardia occurs in the upper chamber while in ventricular in the lower chambers all these 3 conditions result in rapid heartbeat. Pathologically it occurs because of cardiac problems or non-cardiac most commonly hypoxia, pulmonary emboli, dehydration, hypoglycemia, infectious diseases, hematologic and vascular, drug toxicity. Diagnosed by 2D echo, ECG, and other required radiographic and laboratory examinations. Patients are presented with SOB, fatigue, sudden fainting, palpitations, dizziness. Treating the underlying conditions is the only way for this condition followed by non-pharmacological methods like having healthy diet, preventing strenuous exercise.
The Tachycardia (Tachyarrhythmias) drugs in development market research report provide comprehensive information on the therapeutics under development for Tachycardia (Tachyarrhythmias), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tachycardia (Tachyarrhythmias) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Tachycardia (Tachyarrhythmias) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 15 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Tachycardia (Tachyarrhythmias) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Tachycardia (Tachyarrhythmias) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Tachycardia (Tachyarrhythmias) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Academic Pharmaceuticals IncAOP Health
Argenx SE
ARMGO Pharma Inc
Cardurion Pharmaceuticals LLC
Elex Biotech LLC
GEXVal Inc
Grifols SA
Milestone Pharmaceuticals Inc
Saliogen Therapeutics Inc
Solid Biosciences Inc
University of Iowa
University of Oklahoma
Vivasc Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Tachycardia (Tachyarrhythmias) reports